Oral diagnosis of plasmablastic lymphoma: a report of two cases

Plasmablastic lymphoma (PBL) is a rare and aggressive B-cell malignancy that usually has a poor prognosis. Oral manifestations in the PBL are second in frequency, and the most common location is the palate or gingiva. Our study presents 2 cases of PBL with palate manifestation. A 51-year-old, HIV negative man presented an asymptomatic lesion and a female, HIV positive and smoker, presented a symptomatic growth. Clinically, both lesions exhibited a nodule with an ulcerated surface, undefined limits, and a purplish color. An incisional biopsy was performed, with a histopathological diagnosis compatible with plasma cell neoplasm. Immunohistochemical analysis confirmed the diagnosis. They were referred to HematOncology team for treatment, which consisted in DA-EPOCH (dose adjusted etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin) combined with MADIT (combination of methotrexate, cytosine arabinoside, and dexamethasone intrathecal). The male patient is receiving chemotherapy and the female patient died during the 3rd cycle of chemotherapy during COVID-19. Plasmablastic lymphoma (PBL) is a rare and aggressive B-cell malignancy that usually has a poor prognosis. Oral manifestations in the PBL are second in frequency, and the most common location is the palate or gingiva. Our study presents 2 cases of PBL with palate manifestation. A 51-year-old, HIV negative man presented an asymptomatic lesion and a female, HIV positive and smoker, presented a symptomatic growth. Clinically, both lesions exhibited a nodule with an ulcerated surface, undefined limits, and a purplish color. An incisional biopsy was performed, with a histopathological diagnosis compatible with plasma cell neoplasm. Immunohistochemical analysis confirmed the diagnosis. They were referred to HematOncology team for treatment, which consisted in DA-EPOCH (dose adjusted etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin) combined with MADIT (combination of methotrexate, cytosine arabinoside, and dexamethasone intrathecal). The male patient is receiving chemotherapy and the female patient died during the 3rd cycle of chemotherapy during COVID-19.